Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

135.38USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$135.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,526
52-wk High
$208.78
52-wk Low
$75.87

Select another date:

Tue, Nov 27 2018

German stocks - Factors to watch on Nov. 27

BERLIN, Nov 27 The following are some of the factors that may move German stocks on Tuesday:

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

UPDATE 3-Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation won U.S. approval on Monday, according to the Food and Drug Administration's website.

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH, Oct 21 Roche's entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT, Sept 5 Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Select another date: